MAKING HEARING A PRIORITY
CILcare is the world’s leading R&D services company committed to making hearing a priority. Take an in-depth look at how we can support your R&D program to prevent and treat ear disorders.
Discover our services
CILcare will be attending the 16th Annual Discovery on Target on September 25-28, 2018 in Boston. Meet Sylvie COSNIER-PUCHEU, Ph.D, CSO, with her presentation on Preclinical Strategies for Evaluating Treatment Efficacy to Prevent or Cure Auditory Disorders on 27th of...
CILcare will attend the upcoming 4th Annuel Meeting GDR Vertiges in Marseille, which takes place on September 21-22, 2018. Meet Celia Belline, CEO, to learn more about the link between hearing and vestibular disorders. About GDR Vertiges The 2018 Edition of the GDR...
CILcare will be attending MassBio’s CRO/CMO Symposium on September 6th, 2018 in Boston. Meet Aurore MARIE, CILcare's R&D Project Manager, to learn more about cutting-edge GLP preclinical services we offer to developers of auditory therapies. CILcare and CBSET combine...
Pharma / Biotech
Develop new therapies. Repurpose existing drugs in otology.
Innovate with drug delivery devices for the inner ear. Speed up market access of hearing aids.
Develop health food ingredients for the prevention of hearing loss, tinnitus, or otitis.
Improve and develop products to treat ear inflammation in pets.
CILcare, the world leading CRO dedicating to ear disorders
CILcare is a unique CRO specialized in ear disorders. We offer preclinical services and consultancy to accelerate the development of innovative products for hearing loss, tinnitus, and otic disorders.
Because research & development in hearing is as fascinating as it is complex, preclinical studies require perfectly accurate and reproducible measures using state-of-the-art technology in acoustics and electrophysiology. CILcare’s core values lie in our validated and highly robust animal models, enabling us to deliver consistent and valid results.
Drawing from an extensive industrial background, we guide our partners from target identification to IND, and work closely together to advance auditory research and reach a common goal: serve patient population who need our help the most.
Hearing disorders: a high unmet medical need
young people at risk of hearing loss
Disabling hearing loss could affect nearly 1 billion people globally by 2050 according to the WHO. In 2013, 366 million people were affected. This alarming and rapidly growing prevalence mainly results from population growth and aging, modern lifestyles with excessive noise exposure, the intake of ototoxic drugs, and chronic ear infections.
Hearing loss has been ranked as the fourth highest cause of disability worldwide, higher than many other chronic diseases including diabetes, dementia, and chronic obstructive pulmonary disease. Deafness profoundly affects the quality of life of patients and is strongly linked to cognitive decline in the elderly. Unaddressed hearing loss costs countries an estimated US$ 750 billion annually, therefore posing a significant issue to our health systems.
A hundred pharmaceutical and biotechnology companies and thousands of academics are contributing to scientific progress in the auditory field. Although no drugs have been approved by authorities to treat hearing loss and tinnitus yet, some actors are reporting promising scientific research results. These hold the promise of filling an unmet medical need and having transformative impacts on patient populations in the near future.